Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Gotham Asset Management LLC

Gotham Asset Management LLC boosted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 35.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,020 shares of the biopharmaceutical company’s stock after purchasing an additional 7,570 shares during the period. Gotham Asset Management LLC’s holdings in Alexion Pharmaceuticals were worth $3,531,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Commerzbank Aktiengesellschaft FI grew its position in Alexion Pharmaceuticals by 151.5% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after purchasing an additional 79,943 shares in the last quarter. Morgan Stanley grew its position in Alexion Pharmaceuticals by 112.0% during the 1st quarter. Morgan Stanley now owns 585,482 shares of the biopharmaceutical company’s stock worth $70,983,000 after purchasing an additional 309,299 shares in the last quarter. HPM Partners LLC grew its position in Alexion Pharmaceuticals by 267.2% during the 2nd quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 4,861 shares in the last quarter. Principal Financial Group Inc. grew its position in Alexion Pharmaceuticals by 1.2% during the 2nd quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock worth $40,823,000 after purchasing an additional 4,115 shares in the last quarter. Finally, Calamos Advisors LLC grew its position in Alexion Pharmaceuticals by 405.3% during the 2nd quarter. Calamos Advisors LLC now owns 334,488 shares of the biopharmaceutical company’s stock worth $40,697,000 after purchasing an additional 268,287 shares in the last quarter. Hedge funds and other institutional investors own 94.25% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Gotham Asset Management LLC” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.com-unik.info/2017/10/13/alexion-pharmaceuticals-inc-alxn-shares-bought-by-gotham-asset-management-llc.html.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the sale, the director now owns 5,480 shares in the company, valued at $799,038.80. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the sale, the director now owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,190 shares of company stock valued at $2,433,669. Corporate insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business had revenue of $912.00 million during the quarter, compared to analysts’ expectations of $846.15 million. During the same quarter in the prior year, the company posted $1.13 earnings per share. The firm’s revenue was up 21.1% on a year-over-year basis.

Several equities analysts have weighed in on the stock. UBS AG reiterated a “buy” rating and set a $142.00 price objective (up from $140.00) on shares of Alexion Pharmaceuticals in a research report on Monday, June 26th. BidaskClub cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price for the company in a research note on Wednesday, August 2nd. Evercore ISI assumed coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, August 16th. They set an “in-line” rating and a $137.00 target price for the company. Finally, Leerink Swann reissued a “buy” rating and set a $182.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. Six equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $154.56.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

What are top analysts saying about Alexion Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alexion Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit